Introduction
Eccrine porocarcinoma is a rare type of skin cancer originating from eccrine sweat glands or acrosyringium, representing 0.01% of all cutaneous tumors [1] . Since it mainly occurs in the elderly [1, 2] , such patients may possess a high risk of perioperative complications and, in such cases, radical surgical treatment is not practical. In this report, we describe a case of recurrent eccrine porocarcinoma that metastasized to a cervical lymph node successfully treated with CyberKnife.
Case Report
An 85-year-old woman consulted us with a 3-month history of a red nodule. On her initial visit, physical examination revealed a red, easy-to-bleed, dome-shaped nodule 20 mm in diameter on her right cheek ( fig. 1a ). Dermoscopy findings revealed irregular arborizing vessels, and whitish globular structures covered by prominent bleeding ( fig. 1b ). Skin biopsy revealed dense infiltration of clear, cuboidal, basaloid atypical cells throughout the dermis ( fig. 2 ). Immunohistochemical staining revealed that these tumor cells were positive for CEA, 34bE12, p63, CK5/6 and CK14, and negative for GCDFP15. From these results, we diagnosed this case as eccrine porocarcinoma. We resected the tumor with a 2-cm surgical margin. Six months later, lymph node swelling of the right cervical lesion was detected. We screened for a possible internal malignancy with positron emission tomography-computed tomography, which revealed significant enlargement of the cervical lymph nodes ( fig. 3a ). As the lesion was adjacent to the external carotid artery and standard surgical therapy would have been impractical, we employed a CyberKnife. The lesion of the cervical lymph node was irradiated with 50 Gy in 10 fractions. One month after the irradiation, the tumor mass had completely regressed, leaving a scar ( fig. 3b ). There was no severe side effect such as radiation dermatitis at the site of the irradiated lesion. There has been no sign of local recurrence or systemic lesions for 1 year.
Discussion
In this report, we describe a case of recurrent eccrine porocarcinoma that metastasized to a cervical lymph node successfully treated with CyberKnife. Porocarcinoma is described as a biologically aggressive neoplasm that frequently metastasizes to regional lymph nodes [1, 2] . Indeed, Robson et al. [2] reported that approximately 20% of patients with porocarcinoma develop lymph node metastasis. The representative standard therapy for lymph node metastasis is regional lymphadenectomy, but its mortality rate is high [1] [2] [3] . In addition, since patients with porocarcinoma tend to be elderly [2] , they may have a high risk of perioperative complications. Indeed, in our present case, since the lesion was located near critical facial structures and the patient was very old, radical surgical treatment such as cervical lymphadenectomy was not practical. In addition, conventional radiotherapy sometimes induces severe side effects after intensive treatment, and generally has been reported to be of little benefit in both primary and metastatic porocarcinoma, but has mostly been used as a palliative treatment [4] . For these reasons, we selected CyberKnife.
CyberKnife is a robotic image-guided stereotactic radiosurgery device that delivers a large ablative radiation dose to the tumor while sparing normal surrounding tissue. We previously reported successful treatment of a dermatofibrosarcoma protuberance and Merkel cell carcinoma using CyberKnife [5, 6] . As we previously reported [5, 6] , this system is able to deliver extracranial stereotactic radiotherapy with millimetric precision, leading to disease control and toxicity profiles that are equal to or better than other available therapies [7] . To our knowledge, there is no English language report of metastatic porocarcinoma treated with CyberKnife without significant side effects. Our present study suggests the novel possibility of using CyberKnife for the treatment of inoperable metastatic porocarcinoma. Since porocarcinoma tends to recur both in local and remote areas long after the treatment and our follow-up period is short, further follow-up is needed for a definitive conclusion. 
